Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Healthcare
Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of... see more

Recent & Breaking News (CSE:INNO)

Innocan Pharma Reports Third Quarter 2024 Financial Results

Canada NewsWire 15 hours ago

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity

Research 7 days ago

Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand

Canada NewsWire 9 days ago

Innocan Pharma to Present at the 2024 ThinkEquity Conference

GlobeNewswire October 21, 2024

Innocan Pharma to Participate at the ThinkEquity 2024 Investor Conference in New York Also Announces Relaunch of Updated Website for Enhanced Investor Experience

Canada NewsWire October 16, 2024

Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs

Canada NewsWire October 11, 2024

An investor's opportunity in injectable liposomal CBD's potential

Research October 10, 2024

Innocan Pharma Celebrates Dr. Joseph Pergolizzi's Recognition Among Stanford University's List of the Top 2% Most-Cited Scientists Worldwide

Canada NewsWire October 9, 2024

Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting

Canada NewsWire September 3, 2024

Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options

Canada NewsWire August 29, 2024

Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA Registration

Canada NewsWire August 22, 2024

Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over 2.8X to $8.6 Million

Canada NewsWire August 12, 2024

Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center

Canada NewsWire July 26, 2024

Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting

Canada NewsWire July 2, 2024

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Canada NewsWire June 11, 2024

Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million

Canada NewsWire May 27, 2024

FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain

Canada NewsWire May 21, 2024

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Canada NewsWire May 9, 2024

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Canada NewsWire April 22, 2024

Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M

Canada NewsWire April 1, 2024